Human epididymis protein 4 in endometrial cancer: A meta-analysis

Li, Liman; Zhu, Yuxuan; Zhong, Yi; Su, Tan; Fan, Xiaoming; Xi, Qian; Li, Ming-yong; Fu, Jun; Tan, Hong Qi; Liu, Shan

doi:10.1016/j.cca.2018.03.040

Cited by 19 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Existing investigations have suggested that in patients with NSCLC, the expression of HE4 in the cancer tissue is elevated and the serum level of HE4 is increased. [22][23][24] One study further found that HE4 expression in NSCLC tissue was significantly higher than lung benign diseases in female patients. 14 The ROC curve in their study showed that serum HE4 presented the AUC value of 0.78 with a high sensitivity of 91% and a low specificity of 61%.…”

Section: Discussionmentioning

confidence: 99%

“…This study has several important advantages. On the one hand, because HE4 is related to a variety of diseases, such as cancers (ovarian and cervical cancer), abnormal renal function (chronic kidney disease, acute kidney injury), acute or chronic heart failure, fibrosis, and inflammation, 14,[22][23][24][25][26][27][28][29][30][31] we firstly used a combined prediction model (CEA+SCCA+CY21-1+HE4) to evaluate its predictive value on detecting NSCLC. The combined prediction model significantly improved the predictive value of HE4 on detecting NSCLC by increasing the specificity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population

Guo¹,

Song²,

Xiao³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Survival in non-small cell lung cancer (NSCLC) remains poor. Early detection of NSCLC is of great significance to provide a chance to improve survival. Aim: We constructed predictive models to evaluate the predictive value of four tumor biomarkers by including serum human epididymis protein 4 (HE4), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), and cytokeratin 19 fragment (CY21-1) on detecting NSCLC in a Chinese elderly population. Methods: A total of 363 patients with NSCLC and 433 subjects without cancer (healthy control group) were admitted to the respiratory department in our hospital. We assessed serum levels of these four tumor biomarkers in the two groups and then the predictive value of predictive models was evaluated. Results: Serum median values of HE4 (143.3 pmol/L), CEA (4.60 ng/mL), SCCA (1.52 ng/ mL), and CY21-1 (5.36 ng/mL) in patients with NSCLC were significantly higher than the healthy control group, respectively (all P<0.05). A multivariate logistic regression model showed that HE4 (OR=2.10, 95% CI=1.22-4.42, P=0.013), CEA (OR=2.30, 95% CI=1.44-4.53, P=0.004), SCCA (OR=2.20, 95% CI=1.29-4.55, P=0.011), and CY21-1 (OR=2.60, 95% CI=1.56-6.25, P<0.001) were significantly and independently associated with increased risk of NSCLC on admission after confounding factors were corrected. Importantly, the ROC curve suggested HE4 had a good value on predicting NSCLC in the Chinese elderly population. Additionally, the predictive model (CEA+SCCA+CY21-1+HE4) had better idea capability to detecting the existence of NSCLC (AUC=0.954, 95% CI=0.927-0.999, P<0.001). Conclusion:Our study showed that several lung cancer-related biomarkers were used to build prediction models, which has good value for early prediction of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population

Guo¹,

Song²,

Xiao³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…Currently, there is no blood biomarker with sufficient diagnostic accuracy to benefit patient management in endometrial cancer. A number of serum biomarkers, including human epididymis protein 4 (HE4) [34] and cancer antigen 125 (CA-125) [35] have been studied in endometrial cancer, but their low diagnostic performance limits their clinical utility. Multibiomarker panels may have superior discriminatory power compared with individual biomarkers [32,36].…”

Section: Discussionmentioning

confidence: 99%

Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study

Paraskevaidi

Morais

Ashton

et al. 2020

Cancers

View full text Add to dashboard Cite

Endometrial cancer is the sixth most common cancer in women, with a rising incidence worldwide. Current approaches for the diagnosis and screening of endometrial cancer are invasive, expensive or of moderate diagnostic accuracy, limiting their clinical utility. There is a need for cost-effective and minimally invasive approaches to facilitate the early detection and timely management of endometrial cancer. We analysed blood plasma samples in a cross-sectional diagnostic accuracy study of women with endometrial cancer (n = 342), its precursor lesion atypical hyperplasia (n = 68) and healthy controls (n = 242, total n = 652) using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy and machine learning algorithms. We show that blood-based infrared spectroscopy has the potential to detect endometrial cancer with 87% sensitivity and 78% specificity. Its accuracy is highest for Type I endometrial cancer, the most common subtype, and for atypical hyperplasia, with sensitivities of 91% and 100%, and specificities of 81% and 88%, respectively. Our large-cohort study shows that a simple blood test could enable the early detection of endometrial cancer of all stages in symptomatic women and provide the basis of a screening tool in high-risk groups. Such a test has the potential not only to differentially diagnose endometrial cancer but also to detect its precursor lesion atypical hyperplasia—the early recognition of which may allow fertility sparing management and cancer prevention.

show abstract

“…Some of the most reported serum EC biomarkers such as AIBG, SERPINA1 and Apo A1 are high abundance and inflammation-related plasma proteins, limited by their lack of specificity for EC. The two most studied EC biomarker candidates are HE4 (WFDC2) and CA125 (MUC 16), both of which have also been reported in EC tissue specimens and validated in independent cohorts [37,55]. Li and colleagues, in a meta-analysis of 23 studies involving more than 4000 participants, reported a pooled sensitivity and specificity of 0.65 (95% confidence interval (CI) 0.56–0.73) and 0.9(95% CI (0.8–0.95) respectively for HE4 [55].…”

Section: Proteomics Biomarkers For Ec Detectionmentioning

confidence: 99%

“…The two most studied EC biomarker candidates are HE4 (WFDC2) and CA125 (MUC 16), both of which have also been reported in EC tissue specimens and validated in independent cohorts [37,55]. Li and colleagues, in a meta-analysis of 23 studies involving more than 4000 participants, reported a pooled sensitivity and specificity of 0.65 (95% confidence interval (CI) 0.56–0.73) and 0.9(95% CI (0.8–0.95) respectively for HE4 [55]. These findings should be interpreted with caution given the substantial heterogeneity across the studies.…”

Section: Proteomics Biomarkers For Ec Detectionmentioning

confidence: 99%

Proteomic Biomarkers for the Detection of Endometrial Cancer

Njoku

Chiasserini

Whetton

et al. 2019

Cancers

View full text Add to dashboard Cite

Endometrial cancer is the leading gynaecological malignancy in the western world and its incidence is rising in tandem with the global epidemic of obesity. Early diagnosis is key to improving survival, which at 5 years is less than 20% in advanced disease and over 90% in early-stage disease. As yet, there are no validated biological markers for its early detection. Advances in high-throughput technologies and machine learning techniques now offer unique and promising perspectives for biomarker discovery, especially through the integration of genomic, transcriptomic, proteomic, metabolomic and imaging data. Because the proteome closely mirrors the dynamic state of cells, tissues and organisms, proteomics has great potential to deliver clinically relevant biomarkers for cancer diagnosis. In this review, we present the current progress in endometrial cancer diagnostic biomarker discovery using proteomics. We describe the various mass spectrometry-based approaches and highlight the challenges inherent in biomarker discovery studies. We suggest novel strategies for endometrial cancer detection exploiting biologically important protein biomarkers and set the scene for future directions in endometrial cancer biomarker research.

show abstract

Human epididymis protein 4 in endometrial cancer: A meta-analysis

Cited by 19 publications

References 26 publications

The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population

The Prognostic Value of Biomarkers on Detecting Non-Small Cell Lung Cancer in a Chinese Elderly Population

Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study

Proteomic Biomarkers for the Detection of Endometrial Cancer

Contact Info

Product

Resources

About